Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy

NCT00055562 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00055562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy
Lead sponsor
Celgene Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2003
Completion date
December 31, 2004
Enrollment
274
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, neoplasm metastasis